Muscular Dystrophy Canada fund nine new projects through 2023 grant program

NMD4C Investigators involved in many of these exciting clinical and translational research projects

On Thursday March 30th, Muscular Dystrophy Canada (MDC) announced the results of their 2023 Neuromuscular Clinical and Translational Research Grant Program. A dedicated Canadian source of funding for neuromuscular research, this annual funding competition invests in clinical and translational research projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These research grants help fill current gaps in the funding landscape.

This year we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting MDC-funded projects! You can find the full list of funded projects on MDC’s website.

2023 Clinical Research Projects

Establishing the Top Ten Research Priorities for Respiratory Care of Childhood Neuromuscular Disorders ($50,000)

Dr Reshma Amin, respirologist and NMD4C investigator.

Project Lead

Dr Reshma Amin (NMD4C investigator)

The Hospital for Sick Children

NMD4C investigators and collaborators as project co-investigators and collaborators

Dietary Protein Requirements in Adults with Muscular Dystrophy ($100,000)

Project Lead

Dr Tyler Churchward-Venne

McGill University

NMD4C member as project co-investigator

Dr Mark Tarnopolsky

Dr Mark Tarnopolsky

Muscle MRI in neuromuscular disorders. The era of Artificial Intelligence ($100,000)

Hernan-Gonorazky_3x2

Project Lead

Dr Hernan Gonorazky (NMD4C investigator)

The Hospital for Sick Children

NMD4C investigator as project collaborator

B-FIT! Taking exercise away from the hospital into the home environment in people with Oculopharyngeal muscular dystrophy ($100,000)

Project Lead

Dr Eric Voorn

University of Amsterdam

NMD4C investigators and members as project co-investigators and collaborators

Dr Luc Hébert

Dr Luc Hébert

Reimagining Rehabilitation for SMA: Patient and Family Perspectives ($83,166)

Project Lead

Dr Jill Glennis Zwi​​cker

University of British Columbia

NMD4C investigators and members as project co-investigators and collaborators

Translational Research Grants

Therapy development for centronuclear myopathy caused by DNM2 gene changes ($100,000)

james-dowling

Project Lead

Dr James Dowling (NMD4C investigator)

The Hospital for Sick Children

How genealogies (family histories) can help us understand myotonic dystrophy type 1 ($99,600)

Project Lead

Dr Simon Gira​rd

Université du Québec à Chicoutimi

NMD4C investigators as project co-investigators

Evaluating the impact of stop variants  on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle ($100, 000)

Martine tetreault

Project Lead

Dr Martine Tetreault (NMD4C member)

University of Montreal

Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1 ($100 000)

Project Lead

Dr Pascal Chartra​​nd

University of Montreal

Muscular Dystrophy Canada have announced the nine projects funded through their 2023 research grants competition.

Read next...

Ottawa NMD conference poster

Important Deadlines for Ottawa NMD 2023

The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th! 

ENMC mid-career mentoring programme

European Neuromuscular Centre Mid-Career Mentoring Programme Now Open

The European Neuromuscular Centre (ENMC) Mid-Career Mentoring Programme is now open for the third round of mentee candidates!

MNI logo

$6 million Brain Canada grant awarded to McGill to develop virtual integrated patient platform

NMD4C are pleased to share that The Neuro has received a $6 million grant from Brain Canada to fund a new Open Science patient registry to share data with researchers around the world and let patients see how their data is used to develop new treatments for neurological disorders.

xr:d:DAFhueqzCxw:6,j:3799255692,t:23050201

CIHR Report: What we heard on the future of clinical trials

The Canadian Institute of Health Research (CIHR) have recently released an article outlining the results of their building the future of clinical trials consultation in a What We Heard report.

NBS-2023

New Publication from NMD4C Investigators: Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond

A new study ‘Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond’ examines the differences between provincial newborn screening (NBS) programs and the variability of Spinal muscular atrophy (SMA) screening inclusion within these.

Update to national strategy for drugs for rare diseases

National strategy for drugs for rare disease update

Health Canada announced a new funding plan to support the first-ever national strategy for drugs for rare disease, with an investment of $1.5 billion over three years. This national strategy will increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada.